Cabazitaxel
Rx Only
Therapeutic ClassAntineoplastic / Taxane
Common Dose25 mg/m² IV every 3 weeks
Max / 24hAs per body surface area calculation
PregnancyCategory D
Indications ▼
Metastatic castration-resistant prostate cancer (mCRPC) after docetaxel therapy
Mechanism & Pharmacokinetics ▼
Mechanism: Promotes microtubule stabilization, inhibiting depolymerization, leading to cell cycle arrest at G2/M phase and apoptosis of cancer cells.
Pharmacokinetics: Rapid distribution, extensively metabolized by CYP3A4/5 in liver; excreted primarily via feces (~76%), minor renal excretion (~3.7%); half-life ~95 hours.
Dosage & Administration ▼
| Patient Category | Recommended Dose | Max / 24h |
|---|---|---|
| Adults | 25 mg/m² IV over 1 hour every 3 weeks | Per BSA calculation |
| Elderly | Consider dose adjustment for toxicity | Per BSA calculation |
Premedication with corticosteroid, antihistamine, and H2 antagonist recommended to reduce hypersensitivity reactions. Administer via IV infusion only.
Side Effects ▼
Common: Neutropenia, anemia, nausea, vomiting, diarrhea, fatigue
Occasional: Peripheral neuropathy, hypersensitivity reactions, mucositis
Serious: Febrile neutropenia, sepsis, hematuria, renal impairment
Contraindications ▼
Hypersensitivity to cabazitaxel or other taxanes
Severe neutropenia or uncontrolled infections
Drug Interaction ▼
CYP3A inhibitors (e.g., ketoconazole) may increase toxicity
CYP3A inducers (e.g., rifampin) may reduce efficacy
Other myelosuppressive agents: increased risk of neutropenia
Pregnancy & Lactation ▼
Category D: Evidence of fetal risk; use only if benefits outweigh risks
Breastfeeding not recommended during therapy
Clinical / Research Summary ▼
Prostate Cancer Therapy: Improves overall survival in mCRPC patients previously treated with docetaxel.
Pharmacodynamic Advantage: Effective in docetaxel-resistant cancer cells due to poor P-glycoprotein substrate characteristics.
Safety Profile: Myelosuppression is the main dose-limiting toxicity; growth factors may be required.
Research Focus: Combination therapies with prednisone, cabazitaxel dosing optimization, and monitoring neutropenia prophylaxis.
Patient Counseling Points ▼
Administration: IV infusion only; premedicate to prevent hypersensitivity
Monitor: Blood counts prior to each cycle; watch for infection, bleeding, neuropathy
Side effects: Neutropenia, diarrhea, nausea, fatigue; report severe reactions immediately
Drug interactions: Avoid strong CYP3A modulators unless directed by physician
Pregnancy & lactation: Avoid; discuss risks with doctor
Storage & Handling ▼
Store at 2–8°C; protect from light; do not freeze
Keep out of reach of children
Brand Names (Bangladesh & Global) ▼
Jevtana
Medical Disclaimer: This clinical summary is for informational purposes only. Always follow guidance from a qualified healthcare professional for dosage, interactions, and use.
.png)
